Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Relapsed or Refractory Multiple Myeloma

NCT04735575 is registered in ClinicalTrials.gov with Shanghai EpimAb Biotherapeutics Co., Ltd. as lead sponsor.

NCT NCT04735575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04735575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase
Phase 1/2
Overall status
Terminated
Start date
May 20, 2021
Completion date
August 20, 2024
Enrollment
40 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma